New radioactive tracer could spot lung cancer mutations
NCT ID NCT07500987
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a radioactive imaging agent called [111In]-FPI-2107 in 12 Chinese adults with EGFR-mutant non-small cell lung cancer. The goal is to see if it is safe and can help detect tumors on SPECT scans. Participants receive the agent plus an unlabelled antibody beforehand. The study does not aim to treat cancer, only to improve diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[111In]-FPI-2107 (radioactive imaging agent) and FPI-2053 (unlabelled antibody pre-dose)
What this could lead to
If successful, this could lead to a better way to detect EGFR-mutant lung cancer using imaging, helping guide treatment decisions.
What could go wrong
This is a very early Phase I trial with only 12 participants, focused on safety and imaging properties, not treatment. It may not lead to a widely used diagnostic tool.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR MUTATION-POSITIVE NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBeijing, 100142, China
-
Research Site
RECRUITINGShandong, China
-
Research Site
RECRUITINGWuhan, 430022, China